CatalYm
CatalYm develops immune therapies for solid tumors.
$150M Series B+ ·
Led by Bioqube Ventures · Source: fundraisingfox.com
Total raised: $259.04M across 3 sourced rounds
All 3 rounds ↓Signals
About CatalYm
It identifies GDF-15 as a key cancer therapy resistance mechanism and aims to neutralize it. CatalYm's lead antibody, Visugromab, is in clinical trials for patients with relapsed and refractory metastatic solid tumors. The company focuses on advancing its therapies through clinical development.
CatalYm | 2197 days on the record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $150M | fundraisingfox.com | ||
| Series B+ | $50M | endpts.com | ||
| Series B+ | $59.04M | apnews.com |
Timeline
- Website created
Founders and team
- JWJörg Wischhusen Founder
PL
Phil L’Huillier Managing Director and Chief Executive Officer (CEO)AG
Andrea Goddard Chief Technology OfficerAB
Anne Burger CFOCS
Christine Schuberth Wagner Chief Scientific Officer (CSO)CM
Clinton Musil Chief Financial Officer and Chief Business OfficerPG
Peter Garcia Chief Financial OfficerSR
Sujata Rao Chief Medical Officer
Investors
BBayern Kapital
BBioGeneration Ventures
BBioqube Ventureslead investor
BBrandon Capitallead investor
CCanaan Partnerslead investor
CcoparionFForbion Capital Partners
GGilde Healthcare
JJeito Capitallead investor
NNovartis Venture Fund
OOmega Funds
VVesalius Biocapital Partnerslead investor
- WWachstumsfonds Bayern
Companies like CatalYm
NNormunity$75M Series B+ · Jan 2025
OOna Therapeutics$86.6M Series B+ · Oct 2026
TThird Arc Bio$52M Series A · Feb 2026
AArsenal BiosciencesSeries B+ · Oct 2025AA2 Biotherapeutics$80M Series B+ · Jan 2025
IIDRx$120M Series B+ · Aug 2024
Other companies backed by Bioqube Ventures
AActithera$75.5M Series A · Jul 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/catalym (get a free API key).